Literature DB >> 24140477

Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies.

Torben Schiffner1, Quentin J Sattentau, Christopher J A Duncan.   

Abstract

Cell-to-cell spread of human immunodeficiency virus (HIV-1) between immune cells was first observed over 20 years ago. During this time, the question of whether this infection route favours viral evasion of neutralizing antibodies (NAbs) targeting the virus envelope glycoprotein (Env) has been repeatedly investigated, but with conflicting results. A clearer picture has formed in the last few years as more broadly neutralizing antibodies have been isolated and we gain further insight into the mechanisms of HIV-1 transmission at virological and infectious synapses. Nevertheless consensus is still lacking, a situation which may be at least partly explained by variability in the experimental approaches used to study the activity of NAbs in the cell-to-cell context. In this review we focus on the most critical question concerning the activity of NAbs against cell-to-cell transmission: is NAb inhibition of cell-to-cell HIV-1 quantitatively or qualitatively different from cell-free infection? Overall, data consistently show that NAbs are capable of blocking HIV-1 infection at synapses, supporting the concept that cell-to-cell infection occurs through directed transfer of virions accessible to the external environment. However, more recent findings suggest that higher concentrations of certain NAbs might be needed to inhibit synaptic infection, with important potential implications for prophylactic vaccine development. We discuss several mechanistic explanations for this relative and selective loss of activity, and highlight gaps in knowledge that are still to be explored.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Broadly neutralizing; CD4-binding site; Dendritic cell; Envelope; Infectious synapse; Macrophage; T cell; Virological synapse

Mesh:

Substances:

Year:  2013        PMID: 24140477     DOI: 10.1016/j.vaccine.2013.10.020

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  43 in total

1.  Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.

Authors:  Li Liu; Bhavik Patel; Mustafa H Ghanem; Virgilio Bundoc; Zhili Zheng; Richard A Morgan; Steven A Rosenberg; Barna Dey; Edward A Berger
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

Review 2.  Encoded novel forms of HSP70 or a cytolytic protein increase DNA vaccine potency.

Authors:  Tamsin Garrod; Branka Grubor-Bauk; Stanley Yu; Tessa Gargett; Eric J Gowans
Journal:  Hum Vaccin Immunother       Date:  2014-11-19       Impact factor: 3.452

3.  New Connections: Cell-to-Cell HIV-1 Transmission, Resistance to Broadly Neutralizing Antibodies, and an Envelope Sorting Motif.

Authors:  S Abigail Smith; Cynthia A Derdeyn
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

4.  Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.

Authors:  Randi B Gombos; Dror Kolodkin-Gal; Leila Eslamizar; Joshua O Owuor; Emanuele Mazzola; Ana M Gonzalez; Birgit Korioth-Schmitz; Rebecca S Gelman; David C Montefiori; Barton F Haynes; Joern E Schmitz
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

5.  Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins.

Authors:  Seth H Pincus; Kejing Song; Grace A Maresh; Dean H Hamer; Dimiter S Dimitrov; Weizao Chen; Mei-Yun Zhang; Victor F Ghetie; Po-Ying Chan-Hui; James E Robinson; Ellen S Vitetta
Journal:  J Virol       Date:  2017-01-18       Impact factor: 5.103

6.  Molecular Determinants Directing HIV-1 Gag Assembly to Virus-Containing Compartments in Primary Macrophages.

Authors:  Jingga Inlora; Vineela Chukkapalli; Sukhmani Bedi; Akira Ono
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

7.  Short Communication: Exploring Antibody Potential as Prophylactic/Therapeutic Strategies for Prevention of Early Mucosal HIV-1 Infection.

Authors:  Bin Su; Maryse Peressin; Camille Ducloy; Julien Penichon; Luzia M Mayr; Géraldine Laumond; Sylvie Schmidt; Thomas Decoville; Christiane Moog
Journal:  AIDS Res Hum Retroviruses       Date:  2015-09-10       Impact factor: 2.205

8.  Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes.

Authors:  Bin Su; Alexandre Lederle; Géraldine Laumond; Camille Ducloy; Sylvie Schmidt; Thomas Decoville; Christiane Moog
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

9.  The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1.

Authors:  Lihong Liu; Weiming Wang; Julie Matz; Chaobaihui Ye; Lucie Bracq; Jerome Delon; Jason T Kimata; Zhiwei Chen; Serge Benichou; Paul Zhou
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

10.  Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives.

Authors:  P J Klasse
Journal:  Adv Biol       Date:  2014-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.